May 8, 2025 10:47 AM EDT
People

Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff

Kyle LaHucik

Senior Reporter

Vor Bio, found­ed by famed can­cer bi­ol­o­gist Sid­dhartha Mukher­jee, is look­ing for a way out.

Af­ter at­tempt­ing to shake up how blood can­cers are treat­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

ALX On­col­o­gy won’t seek ap­proval for CD47 drug in gas­tric can­cer; Ko­r­ro Bio’s lay­offs

HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times